Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

The Risk Factors For Sporadic Colorectal Cancer
Colorectal cancer (CRC) is one of the most common cancers in China. Although the association between the epidemiological factors and sporadic colorectal cancer has been studied, the relation between smoking, alcohol drinking, family history of cancer, body mass index (BMI) and sporadic colorectal cancer still remains uncertain. So it is important to investigate the role of these factors in the development of sporadic colorectal cancer.
drugs without prescription
3-D Structures With 'DNA Origami'
By combining the art of origami with nanotechnology, Dana-Farber Cancer Institute researchers have folded sheets of DNA into multilayered objects with dimensions thousands of times smaller than the thickness of a human hair. These tiny structures could be forerunners of custom-made biomedical nanodevices such as "smart" delivery vehicles that would sneak drugs into patients" cells, where they would dump their cargo on a specific molecular target.
News of the day
Public Meeting Of Somerset Primary Care Trust Board
The Board of Somerset Primary Care Trust will be holding its next Board meeting at 10.00 am on Wednesday 3rd June 2009 at Wynford House, Lufton Way, Lufton, Yeovil. Somerset. BA22 8HR.
Endocrinology

NovImmune Successfully Completes NI-0801 Phase I Clinical Study

NovImmune, an immunology-focused biotech company dedicated to the development of therapeutic monoclonal antibodies, announced the successful completion of the first phase I clinical study with its fully human monoclonal antibody NI-0801 targeting the chemokine IP-10 (CXCL10) in healthy volunteers. The randomized, doubleblinded, placebo controlled, single centre, phase I study of escalating single intravenous doses of NI-0801 in healthy volunteers (study NI-0801-01) demonstrated that NI-0801 is well tolerated at doses up to and including 20mg/kg. Chemokines are a group of low molecular weight proteins that induce the chemotaxis of different leukocytes to sites of injury or infection. IP-10 is constitutively expressed at low levels in thymic, splenic and lymph node stroma tissues, but its expression can be induced on a variety of cell types including endothelial cells, keratinocytes, fibroblasts, monocytes and neutrophils. IP-10 not only mediates leukocyte recruitment, but also drives T-cell proliferation upon antigenic stimulation. Cell migration in response to chemoattractants requires the retention of IP-10, which is also true for all other chemokines, in the vicinity of the site of inflammation to make sure cells are recruited where they are needed. IP-10 expression at sites of inflammation, leads to local accumulation of specialized cells responsible for the inflammation process in a number of different autoimmune conditions including psoriasis, multiple sclerosis, ulcerative colitis, rheumatoid arthritis, atherosclerosis, liver fibrosis and sarcoidosis. Dr Penelope Ward, Chief Medical Officer commented that "since increased IP-10 (CXCL10) levels correlate with disease severity, an ability to neutralize its effects with a target specific monoclonal antibody offers a promising strategy for the treatment of diseases such as liver fibrosis and lupus, for which therapeutic options are currently limited." NI-0801 is well aligned within NovImmune"s overall expertise and strategy in the field of chemokines to develop potential future therapeutics. Along these lines NovImmune is very happy to have become a member of the European F6 consortium "Innovative Chemokine-based Therapeutic Strategies for Autoimmunity and Chronic Inflammation" (INNOCHEM). Dr Marie Kosco-Vilbois, CSO at NovImmune, commented that "it is a great pleasure and opportunity for NovImmune to be part of a European group of Excellence in the field of future therapeutic applications of the "chemiome", where eminent academic and industrial partners cooperate to translate chemokine biology into effective therapeutics." NovImmune SA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009